Amended Current Report Filing (8-k/a)
January 25 2021 - 9:27AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 2)
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 27, 2020
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, no par value
|
|
AKER
|
|
The
NASDAQ Capital Market
|
Explanatory
Note
This
Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K of Akers Biosciences, Inc. (the
“Company”) filed with the U.S. Securities and Exchange Commission on August 28, 2020, as amended on September 1, 2020
(the “Original Form 8-K”). The Original Form 8-K reported the final voting results of the Company’s 2020 Annual
Meeting of Stockholders held on August 27, 2020 (the “2020 Annual Meeting”). The sole purpose of this Amendment is
to disclose the Company’s decision regarding how frequently it will conduct future stockholder advisory votes to approve
the compensation of the Company’s named executive officers (“Say-on-Pay Vote(s)”). No other changes have been
made to the Original Form 8-K.
Item
5.07 Submission of Matters to a Vote of Security Holders.
As
previously reported in the Original Form 8-K, in an advisory vote held at the 2020 Annual Meeting on the frequency of future Say-on-Pay
Votes, the Company’s stockholders expressed their preference for a Say-on-Pay Vote to be conducted every three years. On
January 22, 2021, the Company’s board of directors considered the outcome of this advisory vote and determined that
future Say-on-Pay Votes will be conducted every three years. The Company’s board of directors will re-evaluate this determination
after the next stockholder advisory vote on the frequency of Say-on-Pay Votes (which will be at the 2026 Annual Meeting of Stockholders,
unless presented earlier).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
Dated:
January 25, 2021
|
/s/
Christopher C. Schreiber
|
|
Christopher
C. Schreiber
|
|
President,
Chief Executive Officer and Director
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024